Printer Friendly

AnGes MG, Avontec Enter into Cross Licensing Agreement for Decoy Nucleic Acid Drug.

Tokyo, Japan, Aug 11, 2005 - (JCNN) - AnGes MG announced on August 10 that it has signed a cross licensing agreement with German bio-venture company Avontec on the development of decoy nucleic acid drugs.

Under the terms of the agreement, AnGes MG will be able to exclusively use Avontec's proprietary technology STAT-1 decoy oligodeoxynucleotides in Asia to develop applications for respiratory and respiratory and skin diseases.

Meanwhile, Avontec will be granted the right to use NF-kappa B decoy oligodeoxynucleotide (NFkB decoy oligo), a kind of nucleic acid medicine developed by AnGes MG, in Europe with a view to applying it to the treatment of psoriasis.

Avontec, which was launched by the Georg-August-University Goettingen in Germany in 2001, specializes in research and development of nucleic acid-based drugs.

Through the partnership, the two companies aim to improve their development capabilities by sharing their expertise.

Source: JCN

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Aug 12, 2005
Previous Article:Nikko Principal, AnGes MG Establish Fund for Pharmaceutical, Medical and Biotechnology Companies.
Next Article:Toray to Provide Japanese Companies with Consulting Service Specialized in China's Fashion Industry.

Related Articles
AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
Nikko Principal, AnGes MG Establish Fund for Pharmaceutical, Medical and Biotechnology Companies.
AnGes MG Patents HVJ Envelope Vector in US.
Hosokawa Micron, AnGes MG Succeed in Creating Composite Nanoparticle Contating NF-Kappa B Decoy Oligodeoxynucleotide.
AnGes MG, Osaka University, Aoki Undertake Co-development of Fully Bioabsorbable Stent.
AnGes MG, FALCO biosystems to Form Business Alliance in Gene Therapy Business.
AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.
AnGes MG to Market and Distribute BioMarin's Naglazyme in Japan.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |